MDxHealth SA Ordinary Shares
MDXHMDxHealth SA is a medical technology company specializing in the development and commercialization of advanced molecular diagnostic tests for the detection and management of prostate and bladder cancers. Leveraging genomic biomarkers, the company aims to enhance personalized treatment decisions and improve patient outcomes in urology.
Company News
MDxHealth reported preliminary 2025 revenues of $109 million (21% YoY growth) with Q4 revenues of $30.5 million (23% YoY growth). The company issued 2026 revenue guidance of $137-140 million (26-28% growth) and expects to achieve a 10% adjusted EBITDA margin run rate by year-end 2026. MDxHealth amended its earnout obligations with Exact Sciences,...
Mdxhealth announced a collaboration with the University of Oxford to initiate Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial, the world's largest randomized clinical trial for localized prostate cancer treatment. This study aims to establish GPS as the first genomic classifier supported by randomized clinical trial evidence...
MDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.
MDxHealth appointed Michael Holder to its Board of Directors as Audit Committee Chair, replacing Regine Slagmulder. CFO Ron Kalfus is resigning, with Scott McMahan assuming interim CFO responsibilities.
The molecular diagnostics market is experiencing significant growth driven by advancements in technology, increasing demand for personalized medicine, and the rising prevalence of chronic diseases. Innovations such as next-generation sequencing (NGS) and PCR-based testing are expanding the scope of molecular diagnostics, enabling early detection ...
